Overview

Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate whether adding the study drug, NP137, to a patient's treatment regimen (before surgery and in combination with chemotherapy afterward) can alter the behavior of pancreatic cancer..
Phase:
PHASE1
Details
Lead Sponsor:
Aram Hezel
Collaborator:
NETRIS Pharma
Treatments:
netrin-1 inhibitor NP137